The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...
Using the Organ Care System (OCS) Heart platform to perfuse, optimize, and assess donor hearts has excellent outcomes, including 87% of extended criteria donor (ECD) hearts being successfully ...
A new medical technology expected to be on the market in 2027 is poised to help patients in middle America have greater access to heart transplants. Xvivo Perfusion, a leader in organ transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results